PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17691917-5	2007	So far, the candidate gene approach has provided important clues for pharmacogenomic-based personalized chemotherapy with 6-mercaptopurine (6-MP), solely metabolized by thiopurine S-methyltransferase (TPMT), and irinotecan, mainly detoxified by UDP-glucuronosyltransferase 1A1 (UGT1A1).	Mercaptopurine	122-138	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	245-276	
23089672-11	2013	Regarding phase II enzyme polymorphism, the anticancer treatment with mercaptopurines and irinotecan is still considered important in relation to the polymorphism of TPMT and UGT1A1, respectively.	Mercaptopurine	70-85	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	175-181	
17691917-5	2007	So far, the candidate gene approach has provided important clues for pharmacogenomic-based personalized chemotherapy with 6-mercaptopurine (6-MP), solely metabolized by thiopurine S-methyltransferase (TPMT), and irinotecan, mainly detoxified by UDP-glucuronosyltransferase 1A1 (UGT1A1).	Mercaptopurine	122-138	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	278-284	
17691917-5	2007	So far, the candidate gene approach has provided important clues for pharmacogenomic-based personalized chemotherapy with 6-mercaptopurine (6-MP), solely metabolized by thiopurine S-methyltransferase (TPMT), and irinotecan, mainly detoxified by UDP-glucuronosyltransferase 1A1 (UGT1A1).	Mercaptopurine	140-144	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	245-276	
17691917-5	2007	So far, the candidate gene approach has provided important clues for pharmacogenomic-based personalized chemotherapy with 6-mercaptopurine (6-MP), solely metabolized by thiopurine S-methyltransferase (TPMT), and irinotecan, mainly detoxified by UDP-glucuronosyltransferase 1A1 (UGT1A1).	Mercaptopurine	140-144	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	278-284	
17691917-6	2007	Reduced activity of TPMT caused by polymorphisms in the TPMT gene and decreased activity of UGT1A1 caused by UGT1A1*28 are related to severe toxic effects of 6-MP and irinotecan, respectively.	Mercaptopurine	158-162	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	92-98	
17691917-6	2007	Reduced activity of TPMT caused by polymorphisms in the TPMT gene and decreased activity of UGT1A1 caused by UGT1A1*28 are related to severe toxic effects of 6-MP and irinotecan, respectively.	Mercaptopurine	158-162	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	109-115	
27641154-7	2017	Polymorphisms in DPYD, TPMT, and UGT1A1 have been described that have a major impact on the pharmacokinetics of 5-fluorouracil, mercaptopurine, and irinotecan, respectively.	Mercaptopurine	128-142	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	33-39